Key Highlights

● Fiscal third-quarter Revenue was $618,676, up from $281,318 a year earlier.

● Quarterly net loss narrowed to $227,939 from $814,192.

● Nine-month revenue was $1,694,482 versus $425,327.

● Management reaffirmed a full-year revenue outlook of $2.3 million.

MedWellAI, Inc. (OTC:MWAI) reported higher revenue and a smaller loss for its fiscal third quarter, and outlined a plan to acquire revenue-generating business-to-business assets. In a release dated May 6, 2026, the Clearwater, Florida company said quarterly revenue was $618,676, up from $281,318. Investors in micro-cap companies may be weighing early growth against the scale of the business.

Latest Company Context

The report covers the three and nine months ended March 31, 2026. Net loss for the quarter was $227,939, compared with $814,192 a year earlier. For nine months, revenue was $1,694,482 versus $425,327, and net loss was $827,961 versus $1,718,272. The company provides AI-driven solutions for business-to-business pharmaceutical, healthcare and wellness markets. Its pharma procurement arm, MedWell USA, sells in-office wellness products, including compounded GLP-1 agonists, and a 24/7 telemedicine service is slated to launch. The comparison between nine-month revenue of about $1.69 million and the full-year outlook of $2.3 million implies a final quarter of roughly $0.6 million, which is similar to the quarter just reported. That would be consistent with the current run rate and does not require a large step up.

Key Business and index Drivers

Strategy is the main driver. Management reaffirmed a full-year revenue outlook of $2.3 million and described a second phase of acquiring several revenue-generating business-to-business assets to build a vertically integrated wellness roll-up. CEO Steve Rubakh said the quarter's results confirm top-line progress and described the company as a differentiated and scalable Investment opportunity; that language is management's own characterisation and not an independent assessment.

Compounded GLP-1 products operate in a regulated area where rules and enforcement can change, which may influence the business. The shares trade on the OTCQB, so no major US index is attached, and quoted prices may be thinly traded. Nine-month revenue of about $1.69 million is already close to the $2.3 million full-year outlook, which may indicate how much further growth is assumed in the final quarter.

What Investors Should Watch

Investors may watch several items. The first is the full-year results against the $2.3 million revenue outlook. The second is whether the telemedicine service launches and contributes revenue. The third is any announced acquisition, including its size, financing and effect on shareholders, since small companies often fund deals with equity. The fourth is progress toward profitability, because the company is still loss-making. The fifth is regulatory developments around compounded GLP-1 products. Investors may also look for audited figures and a clear statement of cash resources, since early-stage companies often rely on outside financing. Management's own words should be treated as claims to verify, not as confirmed results, and updates on regulatory compliance for compounded products would be relevant.

Small Numbers, Large Ambitions

MedWellAI is an early-stage company with rising revenue, narrowing losses and ambitions to consolidate wellness assets. The next filings may show whether growth and acquisitions proceed as planned. Investors may therefore see the next Quarterly Report as a useful checkpoint for execution, particularly on acquisitions, telemedicine and the path toward profitability. Micro-cap companies can show large percentage changes from small bases, so growth rates should be read alongside absolute dollar amounts. Investors may also consider the company's disclosure practices and the limited analyst coverage typical of OTC issuers.